Andrea Luciani
Overview
Explore the profile of Andrea Luciani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Breast cancer in older patients: Can CDK 4/6 inhibitors make the difference in the adjuvant setting?
Dottorini L, Sarno I, Di Menna G, Luciani A, Petrelli F
J Geriatr Oncol
. 2025 Feb;
16(3):102213.
PMID: 39978189
No abstract available.
2.
Petrelli F, Dottorini L, Sarno I, Di Menna G, Angeli I, Moleri G, et al.
Tumori
. 2025 Jan;
:3008916241310991.
PMID: 39885632
Evidence from randomized trials regarding adjuvant chemotherapy and its impact on survival in older patients with resected breast cancer is limited. This study evaluates the current evidence on the use...
3.
Pirovano M, Luciani A, Re Sarto G, Bramati A, Cosmai L
J Nephrol
. 2024 Jul;
38(1):275-278.
PMID: 38972026
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective in non- small cell lung cancer (NSCLC) with EGFR mutations. Since the drug is primally eliminated by...
4.
Mondoni M, Baccelli A, Wahidi M, Belmonte L, Saderi L, Carlucci P, et al.
Respiration
. 2024 Jun;
103(9):563-571.
PMID: 38857571
Introduction: Patients with central neoplasms and haemoptysis show low survival rates. Symptom control without recurrence 48 h after bronchoscopic interventions may improve the prognosis of these patients. Bronchoscopic argon plasma...
5.
Petrelli F, Dottorini L, Stefani A, Vavassori I, Luciani A
J Geriatr Oncol
. 2024 May;
15(6):101792.
PMID: 38802294
Introduction: This study evaluates the effects of radical prostatectomy (RP) or irradiation on overall survival (OS) and prostate cancer-specific mortality (PCSM) in older patients with localized prostate cancer (PC). Materials...
6.
Petrelli F, Ghidini A, Rea C, Parati M, Borgonovo K, Ghidini M, et al.
Curr Probl Cancer
. 2024 Apr;
50:101096.
PMID: 38608530
Introduction: There are multiple neoadjuvant regimens, including platinum agents for triple-negative breast cancer (TNBC), each with a different safety profile, outcome, and pathologic complete response rate (pCR%). We performed a...
7.
Luciani A, Dottorini L, Battaiotto E, Petrelli F
Anticancer Drugs
. 2024 Mar;
35(6):576-583.
PMID: 38527420
Various immunotherapy treatments have received approval for the treatment of advanced non-small cell lung cancer (NSCLC), either as standalone or in conjunction with chemotherapy, contingent upon the extent of PD-L1...
8.
Dottorini L, Ghidini A, Deda R, Sarno I, Cavallone M, Luciani A, et al.
J Geriatr Oncol
. 2024 Mar;
15(4):101741.
PMID: 38462434
Introduction: The introduction of immune checkpoint inhibitors (ICIs) has significantly transformed the treatment landscape for advanced malignancies. These inhibitors bolster the immune system's capacity to detect and destroy cancer cells....
9.
Petrelli F, Antista M, Marra F, Cribiu F, Rampulla V, Pietrantonio F, et al.
Ther Adv Med Oncol
. 2024 Mar;
16:17588359241231259.
PMID: 38435432
Background: Perioperative chemotherapy (CT) is an established therapeutic approach for patients diagnosed with stage IB-III gastric cancer (GC). Objectives: This study aimed to investigate the efficacy of this approach in...
10.
Petrelli F, Rea C, Parati M, Borgonovo K, Ghilardi M, Dottorini L, et al.
Anticancer Res
. 2023 Sep;
43(10):4303-4313.
PMID: 37772569
Background/aim: Low human epidermal growth factor receptor 2 expression (HER2-low: 1+/2+ by immunohistochemistry without HER2 amplification) is emerging as defining a specific breast cancer (BC) subgroup owing to its distinct...